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ABSTRACT 
Background 
Tuberous sclerosis complex is a multisystem genetic disease, caused by mutation in 
the TSC1 or TSC2 genes, associated with many features, including intellectual 
disability (ID). We examined psychometric profiles of patients with TSC1 or TSC2 
mutations and tested if different mutation types were associated with different degrees 
of intellectual ability. 
 
Methods 
One hundred subjects with known TSC1/TSC2 mutations were assessed using a range 
of IQ (intellectual quotient) or DQ (developmental quotient) measures. Effects of 
mutations on TSC1/TSC2 proteins were inferred from sequence data and published 
biochemical studies. 
 
Results 
Most individuals with TSC1 mutations fell on a normal distribution identical to the 
general population, with ~10% showing profound ID. Of individuals with TSC2 
mutations, 34% showed profound ID, and the remainder a pattern of IQ/DQ more 
variable and shifted to the left than in TSC1 or the general population. Truncating 
TSC1 mutations were all predicted to be subject to nonsense-mediated mRNA decay. 
Mutations predicted to result in unstable protein were associated with less severe 
effects on IQ/DQ. There was a statistically significant negative correlation between 
length of predicted aberrant C-terminal tails arising from frameshift mutations in 
TSC1 and IQ/DQ; for TSC2 a positive but not statistically significant correlation was 
observed. 
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Conclusion 
We propose a model where (i) IQ/DQ correlates inversely with predicted levels and/or 
deleterious biochemical effects of mutant TSC1 or TSC2 protein, and (ii) longer 
aberrant C-terminal tails arising from frameshift mutations are more detrimental for 
TSC1 and less for TSC2.  Predictions of the model require replication and 
biochemical testing. 
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INTRODUCTION 
 
Tuberous sclerosis complex (TSC) is a multisystem genetic disease with widespread 
manifestations including neuropsychiatric features such as intellectual disability 
(ID)[1,2]. It is an autosomal dominant disorder caused by mutations in the TSC1 [3] 
or TSC2 [4] genes. Roles attributed to TSC1 include stabilisation and correct 
localisation of TSC2 [5,6]. The TSC1-TSC2-TBC1D7 complex [7-9] modulates 
multiple intracellular processes, notably through TSC2’s GTPase activating protein 
(GAP) domain [10]. The GAP activity of TSC2 counteracts stimulation by RAS-
homologue enriched in brain (Rheb) of mammalian (or mechanistic) target of 
rapamycin complex 1 (mTORC1), which phosphorylates proteins including p70 S6 
kinase (S6K1) [9,11]. TSC1 and TSC2 receive many inputs with activating or 
inhibitory effects on signalling [1], and loss of TSC1/TSC2 disturbs downstream 
signalling. 
 
Intellectual disability (ID) is defined as an Intelligence Quotient (IQ) below 2 
standard deviations of the mean (IQ/DQ <70), and associated functional impairment 
in daily life [12]. Although prevalence of ID in the general population is 
approximately 2.2%, epidemiological analysis of TSC in south-west England showed 
ID prevalence in TSC of 44.4% [13]. The pattern of ID was not a typical unimodal 
Gaussian distribution, but bimodal, with 70% of individuals on a normal distribution 
shifted slightly down (mean (µ) = 93.6, standard deviation (σ) =13.8) and 30% with 
‘profound’ intellectual disability (µ < 20) [13,14]. 
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Until discovery of the roles of the TSC1-TSC2-TBC1D7 complex, it was assumed 
that the predominant causal contributions to intellectual and neurocognitive 
manifestations of TSC were from structural abnormalities (cortical tubers), seizure 
phenomena (epilepsy) or interaction between the two [15,16]. However, de Vries and 
Howe suggested that seizures and tubers were neither necessary nor sufficient to 
explain the neuropsychiatric variability of TSC [17]. For example, less than 50% of 
IQ variance was explained by seizure and tuber factors in the study by O’Callaghan et 
al [16]. Instead de Vries and Howe proposed TSC-associated neuropsychiatric 
disorders to be direct molecular consequences of disturbance of cell 
signalling/development [17 and refs therein]. Supporting this, animal models show a 
direct route from mutation to disruption of neurocognitive functions through mTOR 
overactivation [17-19]. There is also evidence for reversal of neurocognitive 
manifestations by mTOR inhibitors in animal models [19,20] and possibly in humans 
[21].  
 
Consequences of mutations in TSC2 are typically more severe than for TSC1 [22-27]. 
De Vries and Howe proposed that, given that not all mutations were necessarily null, 
different mutations within TSC1 or TSC2 would have different consequences 
according to biochemical effects on the proteins [17]. This raised the possibility of 
using the nature of a given mutation to predict intellectual ability in TSC individuals, 
which could be scientifically and clinically valuable. 
 
To date only three studies of genotype-phenotype associations in TSC utilised 
validated and standardised measures of intellectual ability/developmental level 
[24,27,28]. Lewis et al. [24] measured IQ of 92 individuals with TSC and known 
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mutations, performing a categorical genotype-phenotype analysis, dividing subjects 
into ‘impaired’ and ‘non-impaired’ based on IQ score below or above 70. They 
suggested TSC2 mutations were more likely to be associated with ID than TSC1 
mutations. Jansen and colleagues performed comprehensive neuropsychological 
assessment of 59 TSC subjects [27]. The battery included measures of IQ, memory, 
attentional and executive skills and motor reaction times, and a ‘cognition index’ was 
calculated by summing scaled scores across neuropsychological domains. They 
concluded that TSC1 and TSC2 ‘groups overlapped almost completely’ and prediction 
of cognitive phenotype should not be based on whether an individual had a TSC1 or 
TSC2 mutation. 
 
In the most recent genotype-phenotype study of IQ in TSC, van Eeghen et al. 
examined 137 subjects from a clinical case series [28], utilizing a range of 
standardised IQ/DQ measures. Rates of ID were 23% in those with TSC1 and 59% in 
those with TSC2 mutations, and several inter-mutational correlations were observed, 
some contrasting with earlier findings.  
 
These studies had methodological weaknesses, particularly in the psychometric 
approach to IQ/DQ data. Intelligence is not a categorical phenomenon, being 
normally distributed across a population with µ =100 and σ = 15. Given that IQ/DQ 
distribution in TSC is bimodal, de Vries and Prather suggested that individuals in the 
profoundly impaired range (IQ<20) and those in the normal distribution be considered 
as separate cognitive phenotypes, perhaps representing different underlying 
mechanisms [14]. Statistically, it is inappropriate to perform parametric analysis with 
the TSC distribution pattern. Earlier studies [24,28] did not examine the actual shape 
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of IQ distribution across TSC1 and TSC2, represented by mean and standard deviation 
data.  TSC2 may, for instance, have been reported as more severe than TSC1 because 
most individuals with profound ID had a TSC2 mutation. There are two main 
criticisms of the study by Jansen et al. [27]. In spite of the comprehensive 
neuropsychological battery, scores were collapsed into 4 categories. Given that a 
score of 1 represented performance < 70, more than 50% of the study data would have 
been in this category, preventing separation of mild, moderate, severe and profound 
intellectual disability. Secondly, Jansen’s ‘cognition index’ is of unknown biological 
meaning, since neurobiological substrates of skills such as memory, attention, 
executive skills and motor function are highly different, and mutational or molecular 
correlates may be domain specific.  
 
In van Eeghen et al’s study only 44% of the clinic series had neuropsychological 
evaluations, possibly skewing the sample towards milder phenotypes as shown by the 
low proportion with profound ID [28]. No mean and standard deviation data were 
presented, limiting interpretation of the ‘shape’ of IQ/DQ distributions. Also the study 
did not consider familial/sporadic status (the latter being associated with a more 
severe phenotype [22]) resulting in a possible ascertainment bias. 
 
Given the earlier proposal that different mutation types have different effects [17], we 
tested if different kinds of TSC1 or TSC2 mutations correlated with effects on IQ/DQ. 
We were interested in predicted effects of mutations on levels of mutant proteins 
through nonsense-mediated decay (NMD) or protein degradation (PD). NMD is a 
degradation-mediated reduction in levels of transcripts carrying premature termination 
codons (PTC), occurring if the PTC is shortly before the last exon-exon junction [29]. 
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NMD has been demonstrated for TSC1 but was shown to be incomplete in RNA 
isolated from blood, and from lymphoid and fibroblast cell lines [30], raising the 
possibility that mutant protein might be present in individuals with TSC1 or TSC2 
mutations. We therefore tested for association between the predicted nature of any 
residual mutant protein and phenotype. PD is known to cause significant reduction in 
levels of TSC1 with mutations close to the N terminus [31-33]. 
  
We examined the association between genotype and intellectual phenotype, extending 
and reanalysing the sample used by Lewis et al. [24], and interpret the results in terms 
of a model for stability and effects of mutant proteins. 
 
 
METHODS 
Subjects 
 
Ninety-two unrelated subjects were recruited and assessed as described previously 
(the ‘Cardiff’ study) [24]. An additional 21 unrelated subjects were volunteers from 
the Tuberous Sclerosis Association, UK, recruited for a separate (‘Cambridge’) study 
[34].  After confirmation of clinical criteria for TSC [35], subjects consented for their 
information to be used for research. Protocols received ethical approval. Only subjects 
with complete psychological and genetic profiles were included, excluding 
individuals with no mutation identified, no IQ/DQ score, or undetermined TSC1/TSC2 
status. 
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IQ/DQ assessments 
 
In the Cardiff study, JCL assessed IQ using Wechsler Adult Intelligence Scale 
Revised (WAIS-R) [36], Wechsler Intelligence Scale for Children III (WISC-III) [37], 
Raven’s Coloured Progressive Matrices (RCPM) [38] or the Vineland Adaptive 
Behaviour Scale (VABS) [39]. WAIS-R and WISC-III are standard measures of IQ 
suitable for individuals able to participate in direct testing. The floor of IQ 
measurement using these tools is ~ 45. Although WAIS-R and WISC-III are more 
reliable, they are unsuitable to determine IQs in individuals with lower abilities. In 
these cases the RCPM or VABS may be useful. RCPM is recognised as a measure of 
‘fluid intelligence’ whereas VABS is an indirect measure of adaptive behaviours in 
daily life, used to estimate a developmental quotient (DQ) as proxy for IQ. In the 
Cambridge study, DLM used the Wechsler Abbreviated Scale of Intelligence (WASI), 
WISC-III or WAIS-R [40] to calculate full-scale IQ. Given the challenges of 
measurement across age and ability, we calculated a ‘best estimate IQ/DQ’ using a 
hierarchical approach (WAIS-R/WISC-III > WASI > RCPM > VABS). As per ICD-
10 convention, ID was defined as IQ/DQ < 70 and profound ID as IQ/DQ < 20 [41]. 
 
Mutation detection and categorisation 
 
Mutations were analysed by screening coding sequences and intronic splice site 
regions of TSC1 and TSC2, using single strand conformation polymorphism analysis, 
denaturing high performance liquid chromatography, high resolution melt analysis 
and Sanger sequencing, and assessing both loci for large rearrangements using 
multiplex probe ligation analysis [42,43]. Mutations were categorised as missense, 
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nonsense, frameshift, in-frame deletions, large deletions, splice-site mutations and 
undetermined. Missense mutations were classified as non-conservative if they resulted 
in substitution between biochemical groups as defined by Clustal X [44]. Regions of 
TSC1 and TSC2 considered in mutation mapping are shown in Supplementary Figure 
1. NMD was predicted if the PTC either generated directly by mutation, or resulting 
from a frameshift, was >18 codons upstream of the last exon-exon junction [29].  
Junctions were as in the Leiden Open Variation Database (LOVD) TSC1 and TSC2 
reference sequences [45]. Splice-site mutations, splice variants and possible effects on 
splicing of mutations away from splice sites were not considered, given the lack of 
detailed information on splicing. For frameshifts, the position of the next termination 
codon and the length of the ‘aberrant tail’ between it and the mutation site were 
determined using the LOVD sequences. To predict mutation distributions we assumed 
that each codon in TSC1 and TSC2 was equally likely to mutate to a PTC. Thus 
190/1164 (16.3%) of possible TSC1 truncation or frameshift mutations were predicted 
not to result in NMD, as the final exon-exon boundary occurs 172 codons prior to the 
3’ end of the coding sequence, and 974/1164 (83.7%) were predicted to result in 
NMD. Similarly, 72/1807 (4.0%) of possible TSC2 mutations were predicted not to 
result in NMD and 1735/1807 (96.0%) were predicted to result in NMD. For TSC1 
we carried out additional calculations using the reference sequence to estimate the 
actual number of positions at which a single insertion, deletion or substitution could 
lead to escape from NMD. We assumed insertions and deletions were equally likely, 
and calculated under models in which (i) only transitions occurred or (ii) transitions 
and transversions were equally likely. For TSC1 truncating mutations, PD was 
predicted to occur if the PTC was within the first 350 codons [32], although it is 
recognized that some non-pathogenic mutations in this region may not affect the 
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structure [46] and some mutations outside this region may destabilise the protein. 
Thus 350/1164 (30.1%) of possible truncating mutations were predicted to exhibit 
PD. Predicted and observed numbers of mutations showing PD and/or NMD were 
evaluated from the population sample and from the LOVD database [45]. For TSC2 
truncating mutations, the GAP status was assumed to depend on whether the domain 
was fully intact (present) or truncated (absent).  
 
Statistical Analysis 
 
Data analysis was performed using SPSS version 21. Differences in IQ/DQ scores 
were analysed using the non-parametric Mann-Whitney U test. The Kolmogorov-
Smirnov test was used to assess normality of IQ/DQ distributions above 19. 2x2 
contingency tables were assessed using Fisher’s exact test. Spearman’s rank 
correlation test was used to correlate two independent variables. A threshold of 
p<0.05 was considered statistically significant in all tests and no corrections were 
made for multiple testing. 
 
 RESULTS 
 
Subject characteristics 
Of the 113 participants (92 from the Cardiff study [24] and 21 from the Cambridge 
study [34]), 13 were excluded because intellectual or genetic data were incomplete. 
Of the remaining 100 subjects, 26 had TSC1 and 74 TSC2 mutations. There were 47 
males and 53 females, 82 sporadic and 15 familial cases, with 3 of undetermined 
familial/sporadic origin. Details of mutations are given in Supplementary Table 1. 
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IQ/DQ in TSC1 and TSC2  
IQ/DQ scores (Supplementary Figure 2) were stratified and compared to the expected 
distribution in the general population (Table 1). Proportions with profound 
impairment were 28%, 11% and 34% (all, TSC1 and TSC2 respectively). Excluding 
subjects with profound ID, Kolmogorov-Smirnov tests showed normal distributions 
for remaining IQ scores (All p = 0.574; TSC1 p = 0.915; TSC2 p = 0.551).  
 
 
 
 
Table 1 Stratification of IQ/DQ in the normal population and of all, TSC1 and TSC2 
subjects in the study (n= 100). The lower panel in grey shows subdivisions of the 
category with IQ<70. 
 
IQ Description Normal 
popn (%) 
All subjects 
(%) (n=100) 
TSC1 subjects 
(%) (n=26) 
TSC2 subjects 
(%) (n=74) 
>130 Very superior 2.2 0.0 0.0 0.0 
120-129 Superior 6.7 3.0 11.5 0.0 
110-119 High average 16.1 6.0 7.7 5.4 
90-109 Average  50.0 20.0 42.3 12.2 
80-89 Low average 16.1 12.0 15.4 10.8 
70-79 Borderline 6.7 10.0 3.8 12.2 
<70 Extremely low 2.2 49.0 19.2 59.5 
    50-69 
    35-49 
    20-34 
    <20 
 
           Mild ID 
   Moderate ID 
        Severe ID 
    Profound ID 
                   9% 
                  4% 
                  8% 
                  28% 
             4% 
             4% 
             0% 
             11% 
                   11% 
                   4% 
                   11% 
                   34%  
 
TSC2 was associated with significantly lower IQ/DQ than TSC1 (Table 2) and the 
association held after exclusion of cases with profound ID (IQ<20), and after removal 
of familial cases (reducing possible ascertainment bias). Of those with IQ/DQ>20 (i.e. 
the ‘normal distribution phenotype’ [14]), those with TSC1 mutations were 
psychometrically very similar to the general population (µ=97.5, σ=19.1; compared to 
µ=100.0, σ=15.0). Those with TSC2 mutations showed significantly lower mean IQ 
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and very different psychometric distribution (µ=71.6, σ=27.1). No significant 
difference between males and females was seen across any comparison 
(Supplementary Table 2), with no significant gender differences in the proportion of 
those with ID (males 51.1% vs females 47.1%) or profound ID (males 27.7% vs 
females 28.3%). 
 
 
 
Table 2 Means (µ) and standard deviations (σ) of IQ/DQ with different TSC mutation 
status in the total sample, in those with IQ>20 and in the sporadic cases with IQ>20 
 
TSC status Number µ σ Z value P 
Total sample      
All individuals 100 62.8 36.0   
TSC1 26 88.4 31.2   
TSC2 74 53.8 33.3   
TSC1 vs TSC2    -4.252 <0.001* 
      
IQ >20 only      
All individuals 72 79.9 27.5   
TSC1 23 97.5 19.1   
TSC2 49 71.6 27.1   
TSC1 vs TSC2    -3.878 <0.001* 
      
IQ>20 and sporadic only      
All individuals 54 78.8 26.9   
TSC1 11 94.8 22.9   
TSC2 43 74.7 26.6   
TSC1 vs TSC2    -2.353 0.019* 
Statistical comparisons were made with the Mann-Whitney U test. * denotes a statistically significant 
result.  
 
Mutation Characteristics for TSC1 – NMD, Protein Degradation and TSC2 
interaction 
TSC1 frameshift mutations (Table 3 and Supplementary Fig 3A) were associated with 
significantly lower IQ/DQ than nonsense mutations (difference between mean IQ/DQ 
= 34.9; Z = -2.233; p=0.026). No TSC1 missense mutations were found. All 25 TSC1 
truncating (i.e. nonsense or frameshift) mutations were predicted to result in NMD. 
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Strikingly, all truncating mutations in TSC1 in the LOVD database [45] (2 May 2014) 
were also predicted to result in NMD, which was statistically highly significant 
compared to the null hypothesis that they were evenly distributed throughout the gene  
(p<0.0001, Table 4). Predictions based on the more detailed calculation of sites where 
a single mutation could result in escape from NMD gave similar conclusions (not 
shown).  
 
Table 3 Means (µ) and standard deviations (σ) of IQ/DQ with different mutational 
categories in TSC1 and TSC2 
 
Mutation category Number µ σ Z value P 
TSC1      
Nonsense 14 103.0 16.5   
Frameshift 11 68.1 36.0   
Nonsense vs frameshift    -2.233 0.026* 
      
TSC2      
Nonsense 17 50.1 30.6   
Frameshift 13 56.7 34.2   
Nonsense vs frameshift    -0.558 0.577 
Statistical comparisons were made with the Mann-Whitney U test. The individual with a TSC1 splice 
site mutation is omitted. * denotes a statistically significant result.  
 
 
Table 4 Fisher’s exact tests of the distribution of mutations predicted to be associated 
with nonsense-mediated decay (NMD) and protein degradation (PD) status in the 
sample and of all mutations listed in the TSC1 and TSC2 Leiden Open Variation 
Database (accessed on 2 May 2014). Individuals with splice site mutations are 
omitted. 
 
Type of analysis Expected ratio Observed Ratio Two-tailed P 
value 
 
This study (TSC1 = 25; TSC2 = 30) 
TSC1 (no NMD:NMD) 4:21 0:25 0.111 
TSC2 (no NMD: NMD) 1:29 3:27 0.612 
TSC1 (no PD:PD) 17:8 15:10 0.551 
 
LOVD Database (TSC1 = 588; TSC2 = 1020) 
TSC1 (no NMD:NMD) 96:492 0:588 <0.0001* 
TSC2 (no NMD:NMD) 41:979 45:975 0.741 
TSC1 (no PD:PD) 411:177 417:171 0.749 
* denotes a statistically significant result.  
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The numbers of TSC1 mutations predicted to cause truncation in the region leading to 
protein degradation (‘PD mutations’) rather than the non-PD region (‘no-PD 
mutations’) in our dataset and the LOVD database were not significantly different 
from expectation. However, mutations predicted to result in PD were associated with 
higher IQ/DQ than non-PD mutations (Table 5). When only sporadic cases were 
considered, to reduce ascertainment bias, the difference was even more marked and 
significant (mean difference in IQ/DQ = 45.8; Z = 2.275; p=0.027). Hoogeveen-
Westerveld et al. reported that substitutions in the first 224 amino acids could lead to 
protein instability [33]. Mutations in our dataset causing truncations within this more 
restricted region were also associated with a higher IQ/DQ than mutations leading to 
distal truncations, but sample numbers were too small for statistical analysis. 
Individuals with mutations within the tuberin-interaction domain (TID) of TSC1 
showed higher mean IQ/DQ (n=6, µ=101.3, σ= 13.6) than others (n=19, µ=83.3, σ= 
34.6) and higher mean than those with mutations elsewhere in the first half of the 
protein (n=7, µ=90.4, σ= 16.9). The differences were not significant, although this 
may reflect small sample sizes. 
Table 5 Means (µ) and standard deviations (σ) of IQ/DQ with different expression 
categories in TSC1 and TSC2. Individuals with splice site mutations are omitted. 
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Expression category Number µ σ Z value P 
TSC1      
No PD 15 79.7 37.6   
PD  10 99.5 14.6   
No PD vs PD    1.083 0.279 
      
TSC1 sporadic cases only      
No PD 10 65.5 36.8   
PD 4 111.3 14.2   
No PD vs PD    2.275 0.027* 
      
TSC2      
No NMD 3 31.0 20.8   
NMD 27 55.4 32.2   
No NMD vs NMD    1.383 0.167 
      
TSC2 sporadic cases only      
No NMD 3 31.0 20.8   
NMD 26 55.0 32.7   
No NMD vs NMD    1.326 0.185 
Statistical comparisons were made with the Mann-Whitney U test. * denotes a statistically significant 
result.  
 
 
Correlation of predicted length of aberrant tail in TSC1 and IQ/DQ 
We tested for a correlation between the predicted lengths of aberrant tails generated 
by the frameshift or nonsense mutations and IQ/DQ (Figure 1A and Supplementary 
Table 3). Mutant proteins (frameshift or nonsense, 15 individuals) not predicted to be 
subject to PD showed significant negative correlation between tail length and IQ/DQ 
(rho = -0.706; p = 0.003).  
 
 
Mutation Characteristics for TSC2 - NMD, TSC1 interaction and GAP status 
Unlike TSC1, there were several missense TSC2 mutations (supplementary Fig 3B). 
Most were non-conservative, suggesting that many conservative substitutions would 
be non-pathogenic. The single individual in the sample with a conservative 
substitution (L1594M) showed an IQ/DQ of 19. Van Eeghen et al. found that 
individuals with missense mutations in exons 22-33 were less seriously affected than 
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individuals with mutations elsewhere [28]. In our study there was only one participant 
with a missense mutation in exons 22-33, with IQ/DQ=19. Of the 12 with missense 
mutations elsewhere, five also had IQ/DQ <20.  Missense mutations were associated 
with lower IQ/DQ than truncating mutations, but the difference was not significant 
(n=13, µ=37.8, σ= 29.8 and n=30, µ=52.9, σ= 31.8 respectively, p=0.224). Among 
truncating mutations, there was no significant difference between frameshift and 
nonsense mutations (Table 3). In-frame deletions were associated with a higher 
IQ/DQ (n=4, µ=71.0, σ= 16.8) than truncations, but the sample was too small for 
statistical testing. There were 9 splice site mutations (µ=68.6, σ= 29.8), and 18 large 
deletions (µ=55.8, σ= 39.5).  
 
For TSC2 PTC mutations the numbers of NMD and no-NMD mutations were not 
significantly different from expected, either in our dataset or in the LOVD database 
(Table 4). No-NMD mutations were associated with a lower IQ/DQ than NMD 
mutations (n = 3; µ= 31; σ 20.8; n = 27; µ = 55.4; σ= 32.2), although results were not 
statistically significant (Table 5). 
 
There was one individual with a missense mutation in the TSC1-interaction domain of 
TSC2, defined as extending to the end of exon 11 [47], with IQ/DQ =21. When the 
region considered was extended (HID, dotted line in Supplementary Figure 1) to the 
N-terminal half of TSC2, including exon 22 (and including missense mutations 
potentially affecting the interaction domain as defined by van Eeghen et al.) there was 
no significant difference compared to individuals with missense mutations elsewhere. 
Van Eeghen et al. [28] by contrast found lower IQ/DQ for individuals with mutations 
in the interaction domain. Three of the 30 TSC2 truncating mutations were predicted 
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to result in retention of the GAP domain, whereas 27 were predicted to result in its 
loss. IQ/DQ was not significantly different between the two groups (n = 3; µ=31.0, σ= 
20.8, and n = 27; µ=55.4, σ= 32.2, Z =-1.383; p=0.167).  
 
Correlation of length of aberrant tail in predicted mutant TSC2 proteins and 
IQ/DQ 
After discounting the no-NMD mutations which may result in lower IQ/DQ for other 
reasons (see below) there was a positive, but not statistically significant, correlation 
(rho = 0.308; p = 0.119) between length of predicted aberrant tail and IQ/DQ (Figure 
1B and Supplementary Table 3). However, the nonsense mutations within this group 
showed a wide spread of IQ/DQ values. 
 
 
DISCUSSION 
IQ/DQ distribution 
The IQ/DQ of our patients (Supplementary Figure 2) was comparable to those in 
another epidemiological study in the UK from 2003 [13]. Both studies showed 
bimodal IQ distribution, with similar proportions of ID and profound impairment 
(49.0% vs 44.4% and 28.0% vs 30.5% respectively), and suggesting our sample was 
representative of the TSC population at the time patient phenotypes were assessed.  
 
Even excluding individuals with profound ID, the TSC1 and TSC2 ‘normal 
distribution’ phenotypes [14] remained psychometrically and statistically significantly 
different, with TSC1 individuals psychometrically very similar to the general 
population, and TSC2 individuals associated with significantly lower IQ (Table 2). 
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Results confirmed that the higher proportion of ID in TSC2 was not simply 
attributable to more individuals with profound ID.  
 
The lack of significant difference between males and females in mean IQ 
(Supplementary Table 2) or the proportion of ID (males 51.1% vs females 47.1%) or 
profound ID (males 27.7% vs females 28.3%) refutes earlier, non-standardised reports 
suggesting more ID in males with TSC [25,26], and replicates the observations made 
by van Eeghen et al. [28]. 
  
Mutation characteristics for TSC1 
The lack of TSC1 missense mutations in our sample of 26 individuals is consistent 
with previous reports that such mutations are rare [48]. It was remarkable that all 25 
TSC1 truncating mutations in our sample and all 588 TSC1 truncating mutations in the 
LOVD database were predicted to show NMD. There are two possible interpretations. 
Truncation of the TSC1 protein within the C-terminal 190 residues may have such a 
slight effect that mutations do not cause TSC, and are not seen in a sample of 
individuals chosen because they have the disorder. Alternatively, TSC1 proteins 
truncated within the C-terminal 190 residues may be lethal if present at wild-type 
levels, because of a dominant effect. We favour the latter explanation, for two reasons. 
The TSC LOVD includes 157 TSC1 variants classified as having ‘no known 
pathogenicity’ [45] (Sept 2014) and 25 of these are located in the no-NMD region, 
consistent with expectation if equally distributed. However, none is a truncating 
mutation, although 56% of mutations overall result in truncation. Thus, if truncating 
mutations in the no-NMD region were indeed non-pathogenic, we would expect to see 
examples of them in LOVD. In addition, most truncating mutations in the no-NMD 
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region would be expected to affect the ERM domain (believed to have an important 
role in mediating cell adhesion [49]) and a region involved in interaction with TSC2 
[32]. Although the suggestion that truncating mutants of TSC1 not subject to NMD 
are embryonic-lethal because of dominant effects contrasts with the general view that 
TSC1 mutations have a mild phenotype, it is consistent with the demonstration [31] 
that TSC1 protein with substitutions at positions 50 or 117 can have a dominant 
negative effect, and the suggestion by these authors that protein with mutations 
elsewhere might also have a dominant negative effect [31].  
 
A deleterious effect of mutant TSC1 would also explain our observation that 
individuals with mutations predicted to result in PD showed higher IQ/DQ than those 
with mutations outside the PD region. Because NMD does not lead to complete loss 
of transcripts [30], production of some truncated protein would be expected. We 
propose that this is not immediately degraded, but that lower levels persist for protein 
truncated within the PD region, resulting in less marked effects on IQ/DQ. In fact, 
these individuals showed a mean and standard deviation in IQ/DQ scores essentially 
identical to the general population. Furthermore, although no patients in this study had 
deletions of the entire TSC1 gene, we have observed 13 patients with such deletions in 
a larger diagnostic series and none was reported to have ID. Given the location of the 
TSC2-interaction domain towards the N terminus of TSC1, it is not surprising that 
individuals with mutations in the interaction domain also showed higher IQ/DQ than 
others (although this contrasts with the observation of van Eeghen et al).  
 
Length of aberrant tail on TSC1 
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For individuals with frameshift TSC1 mutations outside the PD region, effects on 
IQ/DQ were greater the longer the aberrant C-terminal tail on the predicted mutant 
protein, and frameshift mutations were associated with lower IQ than nonsense 
mutations. This could be explained if the aberrant tail increases the deleterious 
biochemical effects of the protein (or reduces its rate of degradation), again consistent 
with the notion that mutant protein is detrimental.  
 
Mutation characteristics for TSC2 
Results for TSC2 were quite different from those for TSC1, with no significant 
clustering of mutations in the NMD region in our population or in the TSC2 LOVD 
(Table 4). Although truncating mutations predicted to give rise to NMD were 
associated with a higher IQ/DQ than no-NMD mutations, this was not statistically 
significant (Table 5). These observations suggest that mutant TSC2 proteins truncated 
near the C-terminus are only slightly deleterious in terms of IQ/DQ. The calmodulin-
binding domain, the oestrogen receptor alpha binding site and a target site for the 
ribosomal protein S6 kinase are all within the no-NMD region [47], although the 
functional relevance of these domains has not yet been fully established. 
 
Van Eeghen et al. [28] reported that individuals with missense mutations in TSC2 had 
a higher IQ/DQ than those with premature truncation mutations, whereas we observed 
a tendency for the reverse. This may reflect the smaller sample size in our study. 
Similarly, van Eeghen et al. observed a lower IQ/DQ for individuals with a mutation 
in the first half of the protein compared to those with a mutation in the second half, 
whereas we observed no difference (and a slightly higher IQ/DQ for individuals with 
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a mutation in the TSC1-interaction domain). Like van Eeghen et al., we observed little 
difference between mutations affecting the GAP domain and those that did not. 
 
Length of aberrant tail on TSC2 
In individuals with frameshift mutations, there was a positive but not statistically 
significant correlation between the length of the aberrant tail and IQ (Figure 1B). This 
might be explained if longer aberrant tails led to more effective clearing of mutant 
protein (for which degradation systems have been described [50]) or reduced the 
deleterious effects of mutant protein. 
 
Model for the effects of mutations 
We propose the following model for the different effects of mutant TSC1 and TSC2 
proteins. Mutant TSC1 protein is highly deleterious, although NMD leads to partial 
reduction of the expression of truncated protein. Mutant protein is degraded slowly, 
and has an adverse effect on cognitive functions, including IQ/DQ. Proteins with 
longer aberrant C-terminal tails are more deleterious in this respect. TSC1 protein 
altered or truncated in the N-terminal 200-300 residues is degraded more rapidly, 
causing a less severe phenotype. The model is consistent with observations reported 
by van Eeghen et al. For TSC1, most individuals in their study with truncating 
mutations up to and including exon 5 showed an IQ/DQ of 70 or more, consistent 
with our proposal that more rapid clearance of mutant protein in those individuals, 
leaves them relatively mildly affected [32]. The destabilizing effect of mutations close 
to the N-terminus of TSC1 is consistent with the existence of a conserved, tightly-
folded domain in this region [46].  
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We suggest that levels of truncated TSC2 protein are also reduced through NMD, 
with mutations in the no-NMD region leading to more severe, but not lethal, 
consequences. Mutant protein is degraded more effectively than TSC1, and proteins 
destabilized by having a long aberrant C-terminal tail are less deleterious.  
 
However, it will be important to test biochemically the predictions of the model for 
levels and function of mutant TSC1 and TSC2 proteins. If the predictions are correct, 
it will also be important to understand why longer aberrant C-terminal tails have 
different effects on TSC1 and TSC2.  
 
 
Our analysis solely considered genotypes, and other factors will also affect outcomes, 
illustrated by some individuals with the same mutation having very different IQ/DQ 
(e.g. TSC2 mutations R751X: IQ/DQ 19, 85, 94; Q1192X: IQ/DQ 19, 79 and 
R1459X: IQ/DQ 19, 19, 68). These factors include somatic mosaicism [51], modifier 
genes (perhaps affecting NMD efficiency) [52] and environmental effects such as 
seizures [28] (although tubers and seizures combined accounted for only 47% of the 
variance in IQ in the study of O’Callaghan et al [16]). Nevertheless, it is clear that 
there are differing effects of distinct mutations in TSC1 and TSC2 (and specific 
mutations associated with a mild phenotype have been recognized for some time, e.g., 
[53]). , Larger-scale exploration of the relationship between the molecular 
consequences of TSC mutations, including direct measurements of levels and function 
of mutant proteins in vivo, and intellectual phenotype is required to confirm our 
findings and may lead to discoveries of direct relevance in the clinical setting. 
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Figure Legend 
 
Figure 1 Correlations between IQ/DQ and the length of predicted aberrant C-terminal 
tail of nonsense and frameshift mutations. A) TSC1 mutations with and without 
predicted protein degradation, B) TSC2 mutations not predicted to be subject to NMD. 
For both panels the y-axis indicates IQ/DQ and the x-axis length of the predicted 
aberrant C-terminal tail arising from frameshift mutations (0 for nonsense mutations). 
For TSC1 cases where mutant protein was not expected to be degraded, there was a 
strong negative correlation between the length of the C-terminal aberrant tail and 
IQ/DQ (rho = -0.706; p = 0.003). 
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Supplementary Table 1. List of individual patient mutations, familial or sporadic 
status of mutation and best estimate IQ/DQ by TSC1 and TSC2. 
 Mutation Familial/Sporadic IQ Mutation Familial/Sporadic IQ 
TSC1   TSC2 continued   
      
R37SP Familial 108 S946SP Sporadic 65 
S91X Unknown 86 T993SP Sporadic 99 
S91X Familial 79 R1032X Sporadic 19 
W103X Sporadic 118 G1133FSX Sporadic 95 
S108FSX Unknown 104 Q1192X Sporadic 19 
R245X Sporadic 128 Q1192X Sporadic 79 
Q328X Familial 93 Q1419X Sporadic 73 
Q328X Familial 90 S1433X Sporadic 65 
Q328FSX Familial 98 R1459X Sporadic 73 
S334X Sporadic 99 R1459X Sporadic 19 
T339X Sporadic 100 R1459X Sporadic 19 
H371FSX Sporadic 69 P1497R Sporadic 19 
T417FSX Familial 97 F1499FSX Sporadic 37 
Q527FSX Familial 80 V1531FSX Sporadic 76 
N634FSX Sporadic 19 L1594M Sporadic 19 
Q701FSX Sporadic 19 N1643K Sporadic 117 
R715FSX Sporadic 94 Q1665X Sporadic 20 
W750X Sporadic 109 P1675K Unknown 38 
R786X Sporadic 88 N1681K Sporadic 19 
R786X Sporadic 88 M1691SP Sporadic 72 
E788X Familial 126 M1721SP Sporadic 54 
R804FSX Sporadic 19 P1737FS Sporadic 55 
E890FSX Sporadic 105 R1743P Sporadic 19 
R892FSX Sporadic 45 H1746del Sporadic 65 
Q898X Familial 118 H1746del Sporadic 50 
Q898X Familial 120 H1746del Sporadic 84 
   T1780FS Sporadic 19 
TSC2   F1803FS Sporadic 19 
   Large Deletion Sporadic 24 
L259SP Sporadic 34 Large Deletion Familial 81 
G294E Familial 21 Large Deletion Sporadic 19 
Y336X Sporadic 74 Large Deletion Sporadic 19 
I365DEL Sporadic 85 Large Deletion Sporadic 19 
P419SP Sporadic 87 Large Deletion Sporadic 19 
R458X Sporadic 19 Large Deletion Sporadic 19 
E482SP Sporadic 75 Large Deletion Sporadic 25 
I496FSX Familial 66 Large Deletion Sporadic 105 
R505X Sporadic 80 Large Deletion Familial 41 
Y598X Sporadic 75 Large Deletion Sporadic 82 
R611Q Sporadic 80 Large Deletion Sporadic 19 
R611Q Sporadic 33 Large Deletion Sporadic 19 
R611W Familial 50 Large Deletion Sporadic 105 
R611W Sporadic 19 Large Deletion Sporadic 100 
R611W Sporadic 19 Large Deletion Sporadic 114 
A614D Sporadic 38 Large Deletion Sporadic 100 
T659FSX Sporadic 75 Large Deletion Sporadic 94 
A675FSX Sporadic 41    
V692FSX Sporadic 19    
R751X Sporadic 85    
R751X Sporadic 94    
R751X Sporadic 19    
A765FSX Sporadic 19    
Q785SP Sporadic 19    
Q785SP Sporadic 112    
Y790X Sporadic 19    
L844FSX Sporadic 98    
S879FSX Sporadic 118    
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Supplementary Table 2. Means (µ) and standard deviations (σ) of IQ/DQ with 
different gender in different TSC status. 
 
Gender status Number µ σ Z value P 
All subjects      
Males 47 62.0 36.5   
Females 53 63.5 35.9   
Males vs Females    -0.164 0.870 
      
TSC1      
Males 10 89.3 33.9   
Females 16 87.9 30.6   
Males vs Females    0.343 0.732 
      
TSC2      
Males 37 54.6 33.9   
Females 37 53.0 33.2   
Males vs Females    0.182 0.856 
Statistical comparisons were made with the Mann-Whitney U test. * denotes a statistically significant 
result.  
 
 
Supplementary Table 3. Spearman’s rank correlations for TSC1 and TSC2 aberrant 
tail length and IQ/DQ. Only individuals with nonsense and frameshift mutations are 
included. Individuals with missense (TSC2) or splice site  (TSC1 and TSC2) mutations 
are excluded. 
 
 N ρ P 
TSC1 all subjects 25 -0.539 0.005* 
TSC1 no degradation 15 -0.706 0.003* 
TSC1 degradation 10 0.199 0.582 
TSC1 frameshift 11 -0.552 0.078 
    
TSC2 all subjects 30 0.092 0.628 
TSC2 no NMD 3 0.866 0.333 
TSC2 NMD 27 0.308 0.119 
TSC2 frameshift 13 -0.031 0.921 
TSC2 frameshift NMD 10 0.422 0.224 
* denotes a statistically significant result 
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Supplementary Figure 1. Schematic representation of the regions of the TSC1 and TSC2 proteins considered here. Exon sizes are represented 
approximately to scale. Exon numbers correspond to those in the reference sequences used in the analysis. Numbers of some exons for TSC2 
have been omitted for clarity. NMD = nonsense mediated decay; PD = protein degradation; TID = tuberin interaction domain; HID = hamartin 
interaction domain (see text for discussion of extent of this); GAP = GTPase activating protein; ERM = (Ezrin–Radixin–Moesin)-binding 
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Supplementary Figure 2. Histograms showing the bimodal distribution of IQ/DQ in the study. A) The 
total sample (n = 100), B) TSC1 group (n = 26), C) TSC2 group (n = 74). 
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Supplementary Figure 3. Stacked histogram of IQ/DQ in relation to type of mutation. A) TSC1 
mutations, B) TSC2 mutations. 
 
